LivingGLP1
Study S001792

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01272232
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
846
Start
2011-06-01
Primary completion
2013-01-01
Lead sponsor
Novo Nordisk A/S
Conditions
Metabolism and Nutrition Disorder; Obesity
Interventions
DRUG:liraglutide; DRUG:placebo
Results posted
TRUE
Secondary identifiers
EUDRACT_NUMBER:2008-002199-88; OTHER:U1111-1118-7963; NIH:2008

Registered primary outcomes

  • Change (%) From Baseline in Body Weight (Fasting) [Week 0, week 56]
  • Proportion of Subjects Losing at Least 5% of Baseline Body Weight [at 56 weeks]
  • Proportion of Subjects Losing More Than 10% of Baseline Body Weight [at 56 weeks]

Linked records (16)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0013170Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.
Davies MJ, Diabetes, obesity & metabolism
2018Systematic reviewPMID 28950422DOIregistry reference RESULT:28950422
R0022210Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
O'Neil PM, Diabetes, obesity & metabolism
2017Randomized trialPMID 28386912DOIregistry reference RESULT:28386912
R0025087Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.
le Roux C, Obesity facts
2017Randomized trialPMID 29145215DOIregistry reference BACKGROUND:29145215
R0025365Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.
Steinberg WM, Diabetes care
2017Randomized trialPMID 28473337DOIregistry reference RESULT:28473337
R0025797Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
von Scholten BJ, Journal of diabetes and its complications
2017Randomized trialPMID 28462892DOIcites ClinicalTrials.gov:NCT01272232; registry reference RESULT:28462892
R0025976Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
Bays H, Current medical research and opinion
2017Randomized trialPMID 27817208DOIcites ClinicalTrials.gov:NCT01272232; registry reference RESULT:27817208
R0022244Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.
Overgaard RV, Clinical pharmacokinetics
2016Other trialPMID 27193270DOIregistry reference RESULT:27193270
R0023240Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP, Diabetes, obesity & metabolism
2016Randomized trialPMID 26833744DOIregistry reference RESULT:26833744
R0026209Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
Fujioka K, Obesity (Silver Spring, Md.)
2016OtherPMID 27804269DOIcites ClinicalTrials.gov:NCT01272232; registry reference RESULT:27804269
R0026243EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
O'Neil PM, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2016Randomized trialPMID 27482610DOIregistry reference RESULT:27482610
R0026436Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
Ard J, Diabetes, obesity & metabolism
2016Randomized trialPMID 26744025DOIregistry reference RESULT:26744025
R0027588Missing data in clinical trials for weight management.
McEvoy BW, Journal of biopharmaceutical statistics
2016Narrative reviewPMID 26418188DOIregistry reference RESULT:26418188
R0025894Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ, JAMA
2015Randomized trialPMID 26284720DOIcites ClinicalTrials.gov:NCT01272232; registry reference RESULT:26284720
R0042435Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies (7155500), Figshare
2015Randomized trialcites ClinicalTrials.gov:NCT01272232
R0051008Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial
Michael J. Davies, Diabetologie und Stoffwechsel
2015Randomized trialDOIcites ClinicalTrials.gov:NCT01272232
R0035752SCALE Diabetes: Continually Dosed Liraglutide May Aid Weight Loss in T2DM
Lynne Lederman, MD Conference Express
2014Other trialDOIcites ClinicalTrials.gov:NCT01272232